Nasdaq:VIR
Vir Biotechnology, Inc.
Vir Biotechnology develops and commercializes novel oral medicines for viral diseases using its proprietary antiviral platform.
Key Metrics
Investment Thesis
Bull Case
Investors might consider Vir Biotechnology due to its potential for a successful transition into a new growth phase with next-generation antiviral drugs that could recapture market share in shrinking therapeutic areas. The company's strong cash position of $232.2 million and access to capital markets provide the necessary runway to fund R&D until new products reach commercialization milestones. If the pipeline delivers approved therapies, the stock could appreciate significantly as it re-rates from a declining legacy business to a high-growth biotech profile.
Bear Case
Investors should avoid Vir Biotechnology due to the severe and sustained decline in revenue over the past three years, which erodes confidence in the company's ability to generate sustainable cash flows without further dilution. The massive operating losses and high R&D spend of $456.0 million indicate that the company is burning through its resources at a rate that may not be supported by current or near-term revenue generation. Without a clear path to profitability or major strategic acquisitions, the stock remains exposed to the risks of biotech failure and potential delisting due to lack of liquidity.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (NASDAQ: VIR) is a global biopharmaceutical company dedicated to developing novel medicines for viral diseases through its proprietary antiviral platform. The company leverages deep scientific expertise to create oral treatments for conditions such as Hepatitis C and HIV, serving markets across North America and Europe. Key revenue streams include sales of approved therapies like Epclusa and Vemlidy, alongside ongoing research and development activities focused on next-generation antivirals.
Analysis
Management Discussion
Recent financial performance highlights the challenges Vir Biotechnology faces as it navigates a steep revenue decline from $1.62 billion in 2022 to $68.6 million in 2025, reflecting the loss of major Hepatitis C franchise revenues. Despite this contraction, the company maintained positive cash flow from investing activities of $310.4 million, likely driven by strategic asset sales or partnership transactions, while continuing to invest heavily in R&D at $456.0 million. The net loss of $438.0 million underscores the high cost of developing new therapies to replace fading revenue streams.
Industry Overview
The global antiviral pharmaceutical industry is currently undergoing a period of significant consolidation and transformation as blockbuster drugs like those for Hepatitis C face patent cliffs and generic competition. Companies in this sector are increasingly focusing on HIV treatment markets, which remain lucrative but highly competitive, while seeking breakthroughs in emerging viral threats such as influenza and respiratory syncytial virus. Success in this environment requires deep scientific innovation and strategic partnerships to maintain market relevance.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.62B | $86.2M | $74.2M | $68.6M |
| Cost of Revenue | $146.3M | $2.8M | $845.0K | $26.0K |
| Gross Profit | $1.47B | $83.4M | $73.4M | $68.5M |
| Operating Expenses | $636.4M | $767.7M | $660.5M | $547.9M |
| Operating Income | $833.1M | $-684.3M | $-587.2M | $-479.3M |
| R&D | $474.6M | $589.7M | $506.5M | $456.0M |
| G&A | $161.8M | $178.0M | $119.0M | $92.1M |
| Stock-Based Comp | $102.1M | $111.3M | $78.5M | $49.1M |
| D&A | $6.3M | $18.9M | $14.6M | $11.7M |
| Depreciation | — | — | $14.2M | $11.4M |
| Amortization | $532.0K | $531.0K | — | — |
| Other OpEx | $0 | $0 | $35.0M | $-182.0K |
| Non-Operating Income | $-78.8M | $56.1M | $64.1M | $41.6M |
| Interest Income | — | — | $71.8M | $40.2M |
| Pre-Tax Income | $754.3M | $-628.2M | $-523.1M | $-437.8M |
| Income Tax | $238.4M | $-13.1M | $-1.1M | $217.0K |
| Continuing Ops | $515.8M | $-615.1M | $-522.0M | $-438.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $515.8M | $-615.1M | $-522.0M | $-438.0M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $515.8M | $-615.1M | $-522.0M | $-438.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $2.52B | $1.59B | $1.04B | $514.1M |
| Cash & Equivalents | $848.6M | $241.6M | $222.9M | $232.2M |
| Marketable Securities | $1.52B | $1.27B | $678.1M | $228.8M |
| Accounts Receivable | $0 | — | — | — |
| Prepaid Expenses | $104.4M | $52.5M | $47.7M | $45.1M |
| Other Current Assets | $44.6M | $23.1M | $93.7M | $8.0M |
| Long-Term Assets | $283.0M | $330.8M | $356.4M | $488.7M |
| PP&E (Net) | $105.6M | $96.0M | $63.2M | $55.6M |
| Intangibles | $32.8M | $22.6M | $8.1M | $7.8M |
| Goodwill | $16.9M | $16.9M | $16.9M | $16.9M |
| Operating Leases | $82.6M | $71.2M | $59.7M | $62.1M |
| LT Investments | $23.9M | $105.3M | $190.0M | $314.6M |
| Other LT Assets | $21.2M | $18.9M | $18.4M | $31.7M |
| Total Assets | $2.80B | $1.92B | $1.40B | $1.00B |
| Current Liabilities | $511.0M | $175.4M | $119.7M | $92.8M |
| Accounts Payable | $6.4M | $6.3M | $5.1M | $9.8M |
| Current Leases | $4.1M | $12.9M | $7.8M | $8.8M |
| Deferred Revenue | — | — | — | $0 |
| Taxes Payable | $15.2M | $149.0K | — | — |
| Other Current Liab | $485.2M | $156.1M | $106.8M | $74.2M |
| Long-Term Liabilities | $213.1M | $153.4M | $128.8M | $144.7M |
| LT Operating Leases | $123.8M | $111.7M | $90.1M | $89.1M |
| Other LT Liab | $89.3M | $41.7M | $38.6M | $55.7M |
| Total Liabilities | $724.1M | $328.8M | $248.4M | $237.5M |
| Shareholders' Equity | $2.08B | $1.59B | $1.15B | $765.3M |
| Paid-In Capital | $1.71B | $1.83B | $1.91B | $1.97B |
| Retained Earnings | $377.2M | $-237.8M | $-759.8M | $-1.20B |
| AOCI | $-9.1M | $-815.0K | $-1.7M | $-2.1M |
| Total L&E | $2.80B | $1.92B | $1.40B | $1.00B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $515.8M | $-615.1M | $-522.0M | $-438.0M |
| Non-Cash Adjustments | $1.90B | $273.0M | $167.7M | $47.5M |
| Working Capital Changes | $-757.2M | $-436.7M | $-92.1M | $-1.3M |
| Cash from Operations | $1.66B | $-778.8M | $-446.4M | $-391.8M |
| Capital Expenditures | $68.0M | $21.6M | $7.3M | $4.8M |
| Cash from Investing | $-1.19B | $164.6M | $499.4M | $310.4M |
| Cash from Financing | $34.8M | $7.5M | $4.4M | $3.8M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $504.6M | $-606.7M | $57.4M | $-77.6M |
| Beginning Cash | $363.4M | $868.0M | $261.3M | $318.7M |
| Ending Cash | $868.0M | $261.3M | $318.7M | $241.1M |
Frequently Asked Questions
How does Vir Biotechnology, Inc. make money?
The company's financials reflect a diversified approach centered on three main segments: (1) Commercial sales of approved products including Epclusa, Vemlidy, and Tivicay across global markets; (2) Licensing and collaboration revenues from partnerships that provide upfront payments and milestone earnings; and (3) Extensive research and development expenditures focused on discovering new drug candidates to expand its antiviral pipeline.
What are the main risks for VIR?
The company faces significant revenue volatility as it transitions away from large blockbuster revenues in Hepatitis C following patent expirations and generic competition. Ongoing substantial cash burn from research and development activities poses a liquidity risk, requiring continuous access to capital markets or strategic partnerships. Regulatory uncertainties regarding the approval of new drug candidates and potential changes in healthcare reimbursement policies could impact future growth prospects.
What is VIR's competitive advantage?
Vir Biotechnology possesses a deep bench of world-class scientists with extensive experience in virology and immunology, providing a robust intellectual property portfolio that includes multiple approved patents. Its proprietary antiviral platform enables the rapid identification and optimization of novel compounds, significantly reducing discovery timelines compared to traditional methods. Additionally, the company maintains a strong track record of regulatory success, having received approval from both the US FDA and European EMA for its key therapies.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.